Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
3.680
+0.310 (9.20%)
At close: Nov 6, 2026, 4:00 PM EST
3.830
+0.150 (4.08%)
Pre-market: Nov 9, 2026, 7:24 AM EST
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
238.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 229.28M |
| Bicycle Therapeutics | 83.53M |
| Abeona Therapeutics | 25.52M |
| AC Immune | 23.75M |
| Lineage Cell Therapeutics | 13.08M |
| Evommune | 10.00M |
| Camp4 Therapeutics | 5.32M |
| Cartesian Therapeutics | 1.03M |
IMRX News
- 46 minutes ago - Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors - GlobeNewsWire
- 2 days ago - Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 - GlobeNewsWire
- 4 days ago - Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - GlobeNewsWire
- 5 days ago - Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium - GlobeNewsWire
- 10 days ago - Immuneering reports Q3 EPS (37c), consensus (31c) - TheFly
- 10 days ago - Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 10 days ago - Immuneering Earnings release: Q3 2026 - Filings
- 10 days ago - Immuneering Quarterly report: Q3 2026 - Filings